The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery
Authors
Keywords
-
Journal
JAMA Surgery
Volume 156, Issue 3, Pages e206363
Publisher
American Medical Association (AMA)
Online
2021-01-28
DOI
10.1001/jamasurg.2020.6363
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta‐analysis of the molecular associations of mucinous colorectal cancer
- (2019) I. S. Reynolds et al. BRITISH JOURNAL OF SURGERY
- Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei
- (2019) Alessandra Raimondi et al. Clinical Colorectal Cancer
- Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis
- (2019) Pierre-Emmanuel Bonnot et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival
- (2018) Joel M. Baumgartner et al. ANNALS OF SURGICAL ONCOLOGY
- Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei
- (2018) Kim Govaerts et al. EJSO
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
- (2018) Willemien J. van Driel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unknown
- (2018) JOURNAL OF SURGICAL ONCOLOGY
- HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road?
- (2018) Wim Ceelen EJSO
- Toward the molecular dissection of peritoneal pseudomyxoma
- (2016) F. Pietrantonio et al. ANNALS OF ONCOLOGY
- GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
- (2016) Filippo Pietrantonio et al. Journal of Translational Medicine
- Unknown
- (2016) STATISTICS IN MEDICINE
- Unknown
- (2016) CANCER
- The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
- (2015) S. Kusamura et al. EJSO
- Unknown
- (2015) STATISTICS IN MEDICINE
- Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
- (2014) Sunila Pradeep et al. CANCER CELL
- FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma
- (2014) F. Pietrantonio et al. ONCOLOGIST
- Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States
- (2013) K. Turaga et al. ANNALS OF SURGICAL ONCOLOGY
- The effects of the intraperitoneal administration of oxaliplatin and 5-FU on the healing of colonic anastomoses: an experimental study
- (2011) D. Kanellos et al. Techniques in Coloproctology
- Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach
- (2009) Paul H Sugarbaker EXPERT OPINION ON PHARMACOTHERAPY
- A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei
- (2008) A L Farquharson et al. BRITISH JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More